2014
DOI: 10.1016/s0168-8278(14)60116-1
|View full text |Cite
|
Sign up to set email alerts
|

O114 Results of the Phase 2 Study M12-999: Interferon-Free Regimen of Abt-450/R/Abt-267 + Abt-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
22
0

Year Published

2014
2014
2015
2015

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 26 publications
(22 citation statements)
references
References 0 publications
0
22
0
Order By: Relevance
“…Two studies have examined the effect of sofosbuvir plus RBV, and that of the ‘3D combination' in patients with HCV recurrence after transplant [70,71]. On-treatment response was observed in almost all patients and SVR rates were approximately 70% for sofosbuvir plus RBV [70] and 92% for the ‘3D combination' [71].…”
Section: Treatment Of Hcv Cirrhosis With Ifn-free Regimensmentioning
confidence: 99%
See 1 more Smart Citation
“…Two studies have examined the effect of sofosbuvir plus RBV, and that of the ‘3D combination' in patients with HCV recurrence after transplant [70,71]. On-treatment response was observed in almost all patients and SVR rates were approximately 70% for sofosbuvir plus RBV [70] and 92% for the ‘3D combination' [71].…”
Section: Treatment Of Hcv Cirrhosis With Ifn-free Regimensmentioning
confidence: 99%
“…On-treatment response was observed in almost all patients and SVR rates were approximately 70% for sofosbuvir plus RBV [70] and 92% for the ‘3D combination' [71]. These encouraging results need to be confirmed in larger cohorts of patients but show promise for the rescue of patients with HCV recurrence on liver graft.…”
Section: Treatment Of Hcv Cirrhosis With Ifn-free Regimensmentioning
confidence: 99%
“…There were no predictors of relapse rate. In another phase II study, 34 LT recipients with recurrent hepatitis C (genotype 1, fibrosis B2, treatment-naïve post-LT and C12 months post-LT) were treated with a quadritherapy including ABT-450/r, dasabuvir, ombitasvir and RBV for 24 weeks [17]. Decrease of CNI dose was required because of the inhibition of CYP-3A4 by the ritonavir-boosted PI ABT-450 (sevenfold increase in Tac half-life, threefold increase in CsA half-life).…”
Section: Interferon-free Regimensmentioning
confidence: 99%
“…Indeed SVR rates over 90 % have been observed using a combination of DAAs without interferon in non-cirrhotic patients and in patients with early cirrhosis [12][13][14][15][16]. The first studies in transplant recipients reported a higher rate of SVR, a much better tolerance and less drug-drug interactions [17][18][19]. We will review here the new antiviral strategies after liver transplantation and their impact on the outcome.…”
Section: Introductionmentioning
confidence: 99%
“…As part of a compassionate use program, patients with severe recurrent hepatitis or fibrosing cholestatic hepatitis after liver transplant were treated with sofosbuvir and RBV for 24-48 weeks +/− PEG IFN with 63 % achieving SVR and the majority having improvement in clinical outcomes and liver function tests [43]. The 3D + RBV regimen has also been studied in the post-liver transplant population [44]. Thirty-four patients received the regimen for 24 weeks, and although those with more advanced liver disease were excluded, data so far have shown a 96 % (25/26) SVR 12, which may bring this regimen into play in the near future.…”
Section: Other Patient Populationsmentioning
confidence: 99%